Search

Immunotherapy drugs called checkpoint inhibitors have been a game changer for some people with cancer. But for most patients, these drugs have been disappointing. Researchers are trying to figure out why.

… Thursday, December 7, 2017 Summary A new analysis finds that certain genes people are born with may play a critical role in whether or not checkpoint inhibitors will work. For some people with cancer, immunotherapy drugs called checkpoint inhibitors , which take the brakes off the immune system and allow

Immunotherapy drugs called checkpoint inhibitors are effective against many cancers, including kidney cancer. Learn how these drugs are used to treat both early- and late-stage disease.

… Monday, September 12, 2022 In an effort to improve the prognosis (outcomes) for kidney cancer , more patients are receiving immunotherapy , which activates the body’s own immune system to kill cancerous cells. Here, genitourinary medical oncologist Robert Motzer from Memorial Sloan Kettering Cancer Center

The third-annual Crain’s New York Business Notable in Healthcare list celebrates outstanding individuals in the healthcare community within the New York metropolitan area, and honors their professional, civic, and philanthropic achievements.

… Monday, August 10, 2020 Memorial Sloan Kettering (MSK) is proud to announce that Physician-in-Chief and Chief Medical Officer Lisa M. DeAngelis, MD , and Community Outreach Manager Julia Ramirez, MA , are included on the Crain’s New York Business 2020 Notable in Healthcare list. The list celebrates outstanding

The discovery of a molecular process that slows down cell division could provide new understanding about how some cancers develop.

… Tuesday, April 8, 2014 Summary The discovery of a molecular process that slows down cell division could provide new understanding about how some cancers develop. This image, generated in the lab of molecular biologist Prasad Jallepalli , shows a human cell nucleus — a membrane-enclosed compartment within

Scientists have generated a compound that could potentially be used to create a new type of pain medication that may prevent the side effects of currently available painkillers.

… Tuesday, December 13, 2011 Summary Scientists have generated a compound that could potentially be used to create a new type of pain medication that may prevent the side effects of currently available painkillers. A Memorial Sloan Kettering study suggests that in the future, researchers might be able

Twelve students successfully defended their dissertations and received their PhD degrees at Commencement on May 19.

… Monday, May 23, 2016 Twelve students at the Gerstner Sloan Kettering Graduate School of Biomedical Sciences have successfully defended their dissertations. As part of Memorial Sloan Kettering’s 37th annual academic convocation on May 19, the Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences

It’s rare to meet someone who makes you want to be a better person. Cristy and Alec Fraser are those people — they are inspiring in an extraordinary and life-changing way.

… Thursday, August 26, 2021 It’s rare to meet someone who makes you want to be a better person. Cristy and Alec Fraser are those people — they are inspiring in an extraordinary and life-changing way. On August 15, the Frasers were part of a segment on Good Morning America and then rode their bikes from

At the ASCO meeting in Chicago, MSK medical oncologist William Tap talked about disappointing results from a new sarcoma drug, which didn’t increase survival.

… Sunday, June 2, 2019 Summary At this year’s annual meeting of the American Society of Clinical Oncology (ASCO), MSK medical oncologist William Tap talked about disappointing results from olaratumab, a new sarcoma drug that wasn’t shown to increase survival in a recent study. At this year’s American Society

Memorial Sloan Kettering is one of only a few centers in the U.S. to employ liver-directed therapies – using hepatic arterial infusion (HAI) – in conjunction with a number of systemic agents.

… Wednesday, December 7, 2016 There is a real and significant need to improve clinical outcomes in patients with cholangiocarcinoma by building on first-line chemotherapy regimens and developing novel strategies for treatment in the second-line setting. Cholangiocarcinomas are rare malignancies that arise

Memorial Sloan Kettering Cancer Center (MSK) experts presented findings from their latest foundational and translational cancer research at the American Association for Cancer Research (AACR) Annual Meeting 2024, held April 5 to 10 in San Diego.

… Wednesday, April 10, 2024 Memorial Sloan Kettering Cancer Center (MSK) experts presented findings from their latest foundational and translational cancer research at the American Association for Cancer Research (AACR) Annual Meeting 2024, held April 5 to 10 in San Diego. Highlights included discoveries